With box warnings

Without box warnings

Branded

Generic

2 results

augtyro
(repotrectinib)
E.R. Squibb & Sons, L.L.C.
Usage: AUGTYRO is indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) and for patients aged 12 and older with NTRK gene fusion-positive solid tumors that are advanced or metastatic, or where surgery poses severe risk, and have limited treatment options.
rozlytrek
(ENTRECTINIB)
Genentech, Inc.
Usage: ROZLYTREK is indicated for adults with ROS1-positive metastatic non-small cell lung cancer and for patients over 1 month old with NTRK gene fusion-positive solid tumors that are metastatic or not amenable to surgery. Approval for NTRK indication is accelerated, pending further clinical efficacy confirmation.

Medications for Reactive Oxygen Species 1 Positive Nonsmall Cell Lung Cancer

augtyro